This volume investigates the clinical safety profile, therapeutic efficacy, and public health risks associated with the use of phenylpropanolamine (PPA) in pharmaceutical products. The authors, including Doreen V. Kagan, Jane S. Brody, and John P. Morgan, compile a series of expert papers to evaluate the balance between the drug's utility as a decongestant and its potential for cardiovascular and neurological toxicity. The work provides a comprehensive framework for assessing the implications of over-the-counter medication distribution and the risks of self-medication.

Experts and medical professionals utilize this text as a foundational reference for understanding the pharmacological risks of PPA. Readers frequently note the technical density of the prose, which is intended for an audience of clinicians and researchers.